Eric Ostertag

Nishan de Silva, M.D., is a prominent figure in the biotechnology sector, particularly known for his leadership roles in gene therapy and biopharmaceuticals. He served as the President and Chief Operating Officer of Poseida Therapeutics, Inc., a company focused on developing innovative gene editing technologies and therapies for cancer and orphan diseases. Under his leadership, Poseida advanced multiple clinical programs and raised significant capital to support its research initiatives.13

Educational Background

Dr. de Silva holds a Bachelor of Arts degree in Biology from Harvard University, an M.D. from The University of Pennsylvania School of Medicine, and an MBA with Distinction in Healthcare Management from The Wharton School of the University of Pennsylvania.23

Career Highlights

• Poseida Therapeutics: Led the company through critical phases of development, including overseeing clinical, regulatory, technical operations, finance, and business development. He played a key role in advancing Poseida's lead asset through successful clinical trials.13
• AFYX Therapeutics: Served as CEO, where he directed a Phase 2 clinical trial for a novel treatment in oral lichen planus and successfully raised financing for the program.3
• Selecta Biosciences: Appointed to the Board of Directors, contributing his extensive experience in gene therapy development.2
• Radionetics Oncology: Currently serves as CEO, focusing on developing novel radiotherapeutics for cancer treatment.34

Dr. de Silva's career spans over 20 years in biotechnology operations, venture capital, and healthcare consulting, making him a well-respected leader in the field.23